Welcome to the 13th World Clinical Biomarkers & CDx Summit 2023!

The industry continues to witness a series of triumphs in biomarker-driven therapies and companion diagnostics (CDx). With 157 FDA-approved CDx devices to date and recent collaborations between key biopharma and diagnostic providers such as Bristol Myers Squibb and Foundation Medicine, AstraZeneca, Grail, Servier, and Qiagen, the race to develop more sensitive and more reproductive diagnostics has become even fiercer in 2023.

Across 2 days, 80+ world-class industry stakeholders will address the most critical challenges in Biomarker Discovery & Translational Development, Clinical Biomarker Development, and CDx Development & Commercialization, to provide you with unparalleled insights to:

  • Recognizing biomarkers & CDx development advancements in multiple disease areas spanning oncology and non-oncology indications including NASH, Alzheimer’s & Parkinson's to revolutionize personalized medicine efforts
  • Exploring the regulatory, commercialization, and market access landscapes to take actional measures for the wider adoption and commercialization of testing and enable equitable access for patients
  • Overcoming the challenges of analytically validating clinical biomarkers to ensure clinical trial robustness
  • Utilize bioinformatics and AI for biomarker discovery, patient stratification, and clinical biomarker validation to enhance underlying biology and pathology understanding for biomarkers
  • Collaborate with the hottest CDx developers to supercharge the co-development of therapeutics and companion diagnostics


What's Was New?


80 Biopharma Speakers


500+ Attendees


1 Scientific Poster Session


8+ Hours of In-Person Networking


20+ New Companies

A Snapshot of Who Attendeds:

31633 - Logo Banners (1)

Content & Discussions Not To Miss:

Plenary Stage

  • Hear the latest updates on the current regulatory frameworks for CDx development to facilitate approvals and applications
  • Navigate the reimbursement landscape through cross-sector collaborations to expand access to biomarker testing

Exclusive insights featuring: FDA, Blue Cross Independence, FNIH & TÜV SÜD

Gold Track: Biomarker Discovery & Translational Development

  • Leverage digital pathology, spatial biology and mutli-omics to characterize novel biomarkers in Alzheimer’s and oncology
  • Identify predictive biomarkers to inform dose and patient selection for translational development

Case studies featuring: Eisai, Repare Therapeutics & AstraZeneca

Red Track: Clinical Biomarker Development

  • Uncover the potential utility of surrogate endpoints in assessing safety and efficacy to ensure robust clinical outcomes using novel monitoring tools
  • Utilize AI/ML to drive diagnosis and validation of clinical biomarkers

Clinical journeys from Eli Lilly, Astellas Pharmaceuticals, Gritstone Bio & Sanofi

Blue Track: CDx Development & Commercialization

  • Identify global trends in CDx development to strategically plan your precision medicine portfolio
  • Implement new CDx strategies to bring innovative therapies to the clinic and effectively maximize market access

Strategic insights from Mersana Therapeutics, Janssen, Alexion Pharmaceuticals & Gilead